The group of drugs for the treatment of arterial hypertension is one of the largest on the Russian retail pharmaceutical market. The total sales volume of drugs in this category in 2025 reached RUB 146.7 billion (at retail prices, including VAT). This represents approximately 7.7% of all retail value sales. Compared to the previous year, ruble growth was recorded at +16.1%. Russian interest in this category of drugs continues to grow; over the past year, 421.8 million packages were sold, representing a 3.4% increase over the previous period.

Demand for antihypertensive drugs throughout the year is generally not characterized by pronounced seasonal fluctuations. Sales of these drugs tend to increase somewhat toward the end of the year, influenced by the Russian habit of stocking up on medications before the New Year holidays. In December 2025, pharmacies sold 39.5 million packages of these drugs, with consumers spending RUB 14.5 billion. At the beginning of 2026 (January–February), the market stabilized at 34.5 million packages sold monthly, with a turnover of RUB 12.7 billion.

According to the database "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, drugs affecting the renin-angiotensin system maintain a dominant position in the antihypertensive category. Last year, they accounted for more than half of all packages sold (53%) and over 69% of the value volume. Beta-blockers consistently hold the second position in the structure of physical consumption (29%). The remaining two groups account for only 18% of physical demand in the market. Overall, the demand structure in the studied groups demonstrates long-term stability and shows no significant shifts.

In total, by the end of 2025, there were 294 brands of antihypertensive drugs in retail, represented by 138 corporations. In recent years, more than 25 new products have entered the market, most of them domestically produced.

For three years, the leading position in the group has been held by the brand Edarbi from Nizhpharm. By the end of 2025, its share accounted for 8.7% of value sales in the category. Compared to 2024, demand for the brand increased by 20% in packages, while monetary expenditures increased by 26%. Triplixam from the Servier Group moved up two positions to take second place with a 5% sales share. The brand's long-term dynamics exceeded +34% in value terms and +27% in physical terms. Concor from the German company Merck lost one position over the year and ended in third place with a 4.8% market share. Over the year, spending on it increased by 6%, while physical demand decreased by 2%. The highest sales growth in monetary terms in the top ten was recorded for the combination drug Juperio from Novartis (+43% in rubles). It is worth noting that almost all top brands are presented in the form of combinations containing two or more active ingredients; overall, demand for such therapy is steadily growing, and consumption dynamics significantly outpace those for monotherapy drugs.

Table. TOP-10 Brands of Antihypertensive Drugs (EphMRA groups: C02, C07, C08, C09) by Monetary Sales Volume on the Russian Retail Pharmaceutical Market in 2025